PMID- 12196365
OWN - NLM
STAT- MEDLINE
DCOM- 20021204
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 13
IP  - 9
DP  - 2002 Sep
TI  - HER-2/neu amplification detected by fluorescence in situ hybridization in fine 
      needle aspirates from primary breast cancer.
PG  - 1398-403
AB  - BACKGROUND: The HER-2/neu gene is amplified in 20-30% of human breast cancers and 
      has been shown to have prognostic and predictive value for treatment with 
      chemotherapy, hormone therapy and antibodies against the HER-2/neu domain 
      (trastuzumab). The aim of our study was to evaluate the reliability of HER-2/neu 
      determination by fluorescence in situ hybridization (FISH) on fine-needle 
      aspirates (FNAs) from primary breast cancer patients by comparison with the 
      results obtained by FISH and immunohistochemistry (IHC) on the corresponding 
      histological sections. MATERIALS AND METHODS: HER-2/neu amplification was 
      determined by FISH on 66 breast cancer FNAs. Twenty-three and 36 corresponding 
      formalin-fixed, paraffin-embedded sections were assayed by FISH and by IHC, 
      respectively, in order to detect HER-2/neu amplification and HER-2/neu protein 
      expression. RESULTS: Twenty-seven per cent (18/66) of breast cancer FNAs showed 
      amplification of HER-2/neu by FISH. Paired results by FISH cytology and FISH 
      histology were available in 22 cases. Concordance was 91% (20/22). Paired results 
      by FISH cytology and IHC were available in 36 cases. Concordance was 92% (33/36). 
      Eighteen of 66 breast cancer FNAs were also submitted to flow cytometric DNA 
      analysis. None of the diploid cases showed HER-2/neu amplification by FISH. Six 
      out of the eight aneuploid cases were amplified and two were polysomic. 
      CONCLUSIONS: HER-2/neu gene amplification can be reliably estimated by FISH on 
      breast cancer FNAs and a good correlation has been found between FISH and IHC 
      results from the corresponding histological sections.
FAU - Bozzetti, C
AU  - Bozzetti C
AD  - Departments of Medical Oncology and Pathology, University Hospital, Parma, Italy. 
      oncologia@ao.pr.it
FAU - Nizzoli, R
AU  - Nizzoli R
FAU - Guazzi, A
AU  - Guazzi A
FAU - Flora, M
AU  - Flora M
FAU - Bassano, C
AU  - Bassano C
FAU - Crafa, P
AU  - Crafa P
FAU - Naldi, N
AU  - Naldi N
FAU - Cascinu, S
AU  - Cascinu S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Biopsy, Needle
MH  - Breast Neoplasms/epidemiology/*genetics/*pathology
MH  - Culture Techniques
MH  - Female
MH  - Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Paraffin Embedding
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2002/08/28 10:00
MHDA- 2002/12/05 04:00
CRDT- 2002/08/28 10:00
PHST- 2002/08/28 10:00 [pubmed]
PHST- 2002/12/05 04:00 [medline]
PHST- 2002/08/28 10:00 [entrez]
AID - S0923-7534(19)63790-7 [pii]
AID - 10.1093/annonc/mdf217 [doi]
PST - ppublish
SO  - Ann Oncol. 2002 Sep;13(9):1398-403. doi: 10.1093/annonc/mdf217.